| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Ivosidenib | AG-120,AG120 | Approved | Agios Pharmaceuticals, Celgene, CStone Pharmaceuticals | TIBSOVO | fda | AGIOS PHARMS INC | 2018-07-20 | Acute myeloid Leukemia (AML) | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| BAY-1436032 | BAY-1436032 | Phase Ⅰ | Bayer | Solid tumours, Acute myeloid Leukemia (AML) | Details |
| IDH1 peptide vaccine (German Cancer Research Center) | Phase Ⅰ | German cancer research center | Glioma | Details | |
| IDH-305 | IDH-305,IDH305 | Phase Ⅱ | Novartis | Glioma, Acute myeloid Leukemia (AML), Malignancies | Details |
| Vorasidenib | AG-881 | Phase Ⅲ | Agios Pharmaceuticals, Celgene | Glioma, Solid tumours, Hematological cancer | Details |
| DS-1001 | DS-1001; DS-1001b | Phase Ⅱ | Daiichi Sankyo | Glioma | Details |
| Olutasidenib | FT-2102,FT 2102 | Phase Ⅱ | FORMA Therapeutics | Myelodysplastic syndrome (MDS), Glioma, Solid tumours, Acute myeloid Leukemia (AML) | Details |
| HMPL-306 | HMPL-306 | Phase Ⅰ | Hutchison Medipharma | Solid tumours, Hematological cancer | Details |
This web search service is supported by Google Inc.
A-Z